Mark W. Frohlich - May 23, 2025 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role
Director
Signature
/s/ Raymond Furey (Attorney-in-Fact)
Stock symbol
RIGL
Transactions as of
May 23, 2025
Transactions value $
$0
Form type
4
Date filed
5/28/2025, 05:26 PM
Previous filing
Mar 10, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Frohlich Mark W Director RIGEL PHARMACEUTICALS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO /s/ Raymond Furey (Attorney-in-Fact) 2025-05-28 0001420482

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RIGL Common Stock Award $0 +1.25K $0.00 1.25K May 23, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RIGL Stock Option (Right to Buy) Award $0 +1.5K $0.00 1.5K May 23, 2025 Common Stock 1.5K $18.95 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.
F2 The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors.